What happened to 23andMe stock?

Shares of 23andMe Holding (NASDAQ: ME) stock slipped in Friday morning trading after the genetic data miner announced that it will spend $400 million to acquire on-demand online medical care and pharmacy services platform Lemonaid Health (not to be confused with Lemonade (NYSE: LMND), the insurance provider).

Did GlaxoSmithKline invest in 23andMe?

In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates. Find the latest 23andMe Holding Co. (ME) stock quote, history, news and other vital information to help you with your stock trading and investing.

Is 23andMe holding a good stock to buy?

With a market capitalization of US$1.3b, 23andMe Holding is a decent size, so it is probably on the radar of institutional investors. In the chart below, we can see that institutions are noticeable on the share registry. Let's take a closer look to see what the different types of shareholders can tell us about 23andMe Holding.